Choose Language Russian | English

Panacela Labs, Inc. is a joint venture company founded in 2011 by Cleveland BioLabs (NASDAQ:CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs and Open Joint Stock Company “Rusnano” in conjunction with Roswell Park Cancer Institute, Children’s Cancer Institute Australia and Cleveland Clinic Foundation. Panacela is 66.77% owned by Cleveland BioLabs.

The Company’s lead development program is Mobilan, a nanoparticle-formulated, recombinant non-replicating adenovirus in clinical development as a universal cancer therapy.

Learn more about ongoing trials.

News and Events

  • This section will include future events, organized by Panacela Labs.